Novo Holdings A/S
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Novo Holdings A/S reported 34 stock positions worth $1.7 billion. Its top holding was VG Morningstar TS MKT ETF-US (VTI) at 18.2% of the portfolio, followed by Brookfield (BN, 9.7%) and Tempus AI Class A (TEM, 8.3%). Compared with Q3 2024, it opened 3 new positions, sold out of 6, added to 6 and reduced 6. The biggest buy was a new position in Recursion Pharmaceuticals-A (RXRX) and the biggest sale an exit from Corcept Therapeutics (CORT).
- Most Recent 13F
- Q2 2026
- Location
- HELLERUP, G7
- CIK
- 0001388325
- Portfolio Value
- $1.7B (Q4 2024)
- SEC Filing
- 0000950123-25-002801 ↗ filed Feb 14, 2025
Holdings Value
Holdings 34 stocks · $1.7B
| VTI VG Morningstar TS MKT ETF-US | 18.22% | 1,038,550 | $301.0M | No change |
| BN Brookfield Corp. | 9.73% | 2,798,830 | $160.8M | Reduce -19.8% |
| TEM Tempus AI Inc. Class A | 8.33% | 4,074,419 | $137.6M | No change |
| EWTX Edgewise Therapeutics Inc. | 8.08% | 5,000,000 | $133.5M | Reduce -9.9% |
| ASML ASML Holding NV-NY Reg SHS | 6.96% | 165,836 | $114.9M | Add +24.4% |
| CRM Salesforce Inc. | 5.95% | 293,901 | $98.3M | Reduce -20.3% |
| RXRX Recursion Pharmaceuticals-A | 4.14% | 10,114,633 | $68.4M | New |
| MIRM Mirum Pharmaceuticals Inc. | 3.76% | 1,500,000 | $62.0M | No change |
| PCVX Vaxcyte Inc. | 3.72% | 750,000 | $61.4M | No change |
| INSM Insmed Inc. | 3.03% | 724,666 | $50.0M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 2.97% | 960,215 | $49.1M | Reduce -4.0% |
| VRDN Viridian Therapeutics Inc. | 2.61% | 2,250,000 | $43.1M | Reduce -5.7% |
| AVBP Arrivent Biopharma Inc. | 2.45% | 1,520,627 | $40.5M | Add +1.0% |
| BABA Alibaba Group Holding-SP ADR | 2.32% | 452,327 | $38.4M | Reduce -9.7% |
| PHVS Pharvaris NV | 2.00% | 1,725,000 | $33.1M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 1.95% | 490,000 | $32.2M | No change |
| MRUS Merus NV | 1.91% | 750,000 | $31.5M | Add +7.1% |
| CLDX Celldex Therapeutics Inc. | 1.53% | 1,000,000 | $25.3M | Add +3.8% |
| CRGX Cargo Therapeutics Inc. | 1.45% | 1,663,724 | $24.0M | Add +7.8% |
| FOLD Amicus Therapeutics Inc. | 1.43% | 2,500,000 | $23.6M | No change |
| LANZATECH GLOBAL INC | 1.31% | 15,814,845 | $21.7M | No change |
| BPMC Blueprint Medicines Corp. | 0.92% | 175,000 | $15.3M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 0.84% | 1,100,000 | $13.8M | No change |
| VERV Verve Therapeutics Inc. | 0.82% | 2,400,000 | $13.5M | No change |
| ZBIO Zenas Biopharma Inc. | 0.79% | 1,600,000 | $13.1M | Add +39.1% |
| CBLL Ceribell Inc. | 0.52% | 328,809 | $8.5M | New |
| FDMT 4D Molecular Therapeutics Inc. | 0.51% | 1,500,000 | $8.4M | No change |
| LXEO Lexeo Therapeutics Inc. | 0.45% | 1,122,581 | $7.4M | No change |
| KYTX Kyverna Therapeutics Inc. | 0.42% | 1,850,000 | $6.9M | No change |
| MERSANA THERAPEUTICS INC | 0.37% | 4,250,000 | $6.1M | New |
| ABCL Abcellera Biologics Inc. | 0.20% | 1,126,915 | $3.3M | No change |
| IOBTQ Io Biotech Inc. | 0.19% | 3,354,449 | $3.1M | No change |
| MQ Marqeta Inc. | 0.10% | 441,558 | $1.7M | No change |
| DMRA Damora Therapeutics Inc. filed as GALECTO INC | 0.03% | 99,913 | $465K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| CORT Corcept Therapeutics Inc. | Sold out | 0.00% | −5.54 |
| CABO Cable One Inc. | Sold out | 0.00% | −2.06 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −1.62 |
| BAM Brookfield Asset Mgmt-A | Sold out | 0.00% | −1.47 |
| BABA Alibaba Group Holding-SP ADR | Reduce -9.7% | 2.32% | −0.32 |
| MGX Metagenomi Therapeutics Inc. | Sold out | 0.00% | −0.19 |
| VRDN Viridian Therapeutics Inc. | Reduce -5.7% | 2.61% | −0.08 |
| SPRO Spero Therapeutics Inc. | Sold out | 0.00% | −0.03 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -4.0% | 2.97% | +0.43 |
| BN Brookfield Corp. | Reduce -19.8% | 9.73% | +0.52 |
| EWTX Edgewise Therapeutics Inc. | Reduce -9.9% | 8.08% | +0.73 |
| CRM Salesforce Inc. | Reduce -20.3% | 5.95% | +0.94 |
Portfolio Buys Q3 2024 → Q4 2024
| RXRX Recursion Pharmaceuticals-A | New | 4.14% | +4.14 |
| ASML ASML Holding NV-NY Reg SHS | Add +24.4% | 6.96% | +1.44 |
| AVBP Arrivent Biopharma Inc. | Add +1.0% | 2.45% | +0.70 |
| CBLL Ceribell Inc. | New | 0.52% | +0.52 |
| MERSANA THERAPEUTICS INC | New | 0.37% | +0.37 |
| MRUS Merus NV | Add +7.1% | 1.91% | +0.17 |
| CRGX Cargo Therapeutics Inc. | Add +7.8% | 1.45% | +0.04 |
| CLDX Celldex Therapeutics Inc. | Add +3.8% | 1.53% | −0.10 |
| ZBIO Zenas Biopharma Inc. | Add +39.1% | 0.79% | −0.17 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $1.7B | EWTX, ASML, COAG, BN, MPLT |
| Q1 2026 | 22 | $1.2B | EWTX, BN, ASML, MIRM, MPLT |
| Q4 2025 | 24 | $1.3B | BN, EWTX, ASML, MIRM, CRM |
| Q3 2025 | 27 | $1.6B | VTI, BN, ASML, MIRM, EWTX |
| Q2 2025 | 29 | $1.4B | VTI, BN, ASML, CRM, MIRM |
| Q1 2025 | 31 | $1.3B | VTI, BN, EWTX, ASML, CRM |
| Q4 2024 | 34 | $1.7B | VTI, BN, TEM, EWTX, ASML |
| Q3 2024 | 37 | $2.0B | VTI, TEM, BN, EWTX, CORT |
| Q2 2024Amended | 38 | $1.9B | VTI, BN, TEM, ASML, CRM |
| Q1 2024 | 35 | $1.4B | ASML, BN, CRM, EPC, CORT |